Autopsy report · NCT04874194

Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1

“The study terminated early because the company was longer providing the investigational product.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 8 months before it started.
• Ran for about 2 years 9 months before it stopped.
• 24 participants enrolled.
• Results were posted on the registry 1 year 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

M.D. Anderson Cancer Center

Sponsor type

University, hospital or other

Conditions

Hematopoietic and Lymphoid Cell Neoplasm; Recurrent Acute Biphenotypic Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Biphenotypic Leukemia; Refractory Acute Myeloid Leukemia

Interventions

Omacetaxine Mepesuccinate; Venetoclax

Participants

24

Sites

1

Countries

United States

Trials that died the same way

• PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer
  “The study was terminated early due to company decision.” (88% match in meaning)
• Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis
  “This study was terminated early due to company decision.” (86% match in meaning)
• An Evaluation of a Novel Food Product in Adults Residing in an Area Endemic for Helminths
  “Due to a business decision to stop the project, the study was terminated early.” (84% match in meaning)
• Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients
  “Study was terminated early for strategic reasons. Only Part I of the study was completed.” (83% match in meaning)
• Measuring Relative Afferent Pupillary Defect
  “The study was terminated early for administrative reasons.” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.